Abstract
Background: Hemoglobin is released to the serum after erythrocyte lyses. Haptoglobin is responsible for carrying hemoglobin into the serum. In hemolytic disease, the amount of hemoglobin which is released to the serum is high; however, the amount of haptoglobin is not enough for binding all the released hemoglobins. Free hemoglobin has peroxidase activity (a pseudoenzyme) and has been indicated to be harmful for patients. This study is focused on the effect of cimetidine on peroxidase activity of hemoglobin.
Methods: Erythrocytes were lysed to obtain hemoglobin. Peroxidase activity of hemoglobin was detected using o-dianisidine and H2O2 as substrates.
Results: Our results showed that the drug operated as an activator for the pseudoenzyme. Cimetidine bound to the pseudoperoxidase in an un-competitive manner and decreased the Km. Half maximal effective concentration (EC50) of cimetidine was determined to be about 12.5 mM. Alkaline pH increased the rate of reaction. Arrhenius plot showed that the activation energies of reactions in the absence and presence of drug were about 10.5 kJ/mol and 7.65 kJ/mol, respectively.
Conclusions: The results demonstrated that cimetidine activates the peroxidase activity of free hemoglobin. Hence, it is suggested that the prescription of cimetidine for the patients with hemolyses diseases may enhance the harmful effects of free hemoglobin in these patients.
References
1. Wassell J. Haptoglobin: function and polymorphism. Clin Lab 2000;46:547–52.Search in Google Scholar
2. Polticelli F, Bocedi A, Minervini G, Ascenzi P. Human haptoglobin structure and function–a molecular modelling study. FEBS 2008;275:5648–56.10.1111/j.1742-4658.2008.06690.xSearch in Google Scholar
3. Alayesh AI. Haptoglobin: old protein with new functions. Clin Chim Acta 2011;412:493–8.10.1016/j.cca.2010.12.011Search in Google Scholar
4. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018–31.10.1016/S0140-6736(10)61029-XSearch in Google Scholar
5. Parker CJ. Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2012;19:141–8.10.1097/MOH.0b013e328351c348Search in Google Scholar
6. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008;371:64–74.10.1016/S0140-6736(08)60073-2Search in Google Scholar
7. Gyan B, Kurtzhals JA, Akanmori BD, Ofori M, GokaBQ, Hviid L, et al. Elevated levels of nitric oxide and low levels of haptoglobin are associated with severe malarial anaemia in African children. Acta Trop 2002;83:133–40.10.1016/S0001-706X(02)00109-2Search in Google Scholar
8. Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, Lemon DD. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 2004;36: 685–97.10.1016/j.freeradbiomed.2003.11.030Search in Google Scholar PubMed
9. Heyman SM, Rosen S, Fuchs S, Epstein FH, Brezis M. Myoglobinuric acute renal failure in the rat: A role for medullary hypoperfusion, hypoxia, and tubular obstruction. J Am Soc Nephrol 1996;7:1066–74.10.1681/ASN.V771066Search in Google Scholar PubMed
10. Davis CL, Kausz AT, Zager RA, Kharasch ED, Cochran RP. Acute renal failure after cardiopulmonary bypass is related to decreased serum ferritin levels. J Am Soc Nephrol 1999;10:2396–402.10.1681/ASN.V10112396Search in Google Scholar PubMed
11. Nagy E, Jeney V, Yachie A, Szabo RP, Wagner O, Vercellotti GM, et al. Oxidation of hemoglobin by lipid hydroperoxide associated with low-density lipoprotein (LDL) and increased cytotoxic effect by LDL oxidation in heme oxygenase-1 (HO-1) deficiency. Cell Mol Biol 2005;51:377–85.Search in Google Scholar
12. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785–92.10.1172/JCI115499Search in Google Scholar PubMed PubMed Central
13. Miller YI, Altamentova SM, Shaklai N. Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin. Biochemistry 1997;36:12189–98.10.1021/bi970258aSearch in Google Scholar PubMed
14. Clark WG, Brater DC, Johnson AR. Goth’s medical pharmacology, 12th ed. USA: Mosby Company, 1988:210–3.Search in Google Scholar
15. Morris T, Rhodes J. Antacids and peptic ulcer-a reappraisal. Gut 1979;20:538–45.10.1136/gut.20.6.538Search in Google Scholar PubMed PubMed Central
16. Babb RR. Cimetidine in preventing or treating acute upper gastrointestinal tract hemorrhage. West J Med 1984;140:478–82.Search in Google Scholar
17. Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 1983;8:463–95.10.2165/00003088-198308060-00001Search in Google Scholar PubMed
18. Richards DA. Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. J Clin Gastroenterol 1983;5:81–90.10.1097/00004836-198312001-00008Search in Google Scholar PubMed
19. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013;121:1276–84.10.1182/blood-2012-11-451229Search in Google Scholar PubMed PubMed Central
20. Reeder BJ. The redox activity of hemoglobins: from physiologic functions to pathologic mechanisms. Antioxid Redox Signal 2010;13:1087–123.10.1089/ars.2009.2974Search in Google Scholar PubMed
21. Minai-Tehrani D, Khodai S, Aminnaseri S, Minoui S, Sobhani-Damavadifar Z, Alavi S, et al. Inhibition of renal alkaline phosphatase by cimetidine. Drug Metab Lett 2011;5:197–201.10.2174/187231211796904982Search in Google Scholar PubMed
22. Levine M, Law EY, Bandiera SM, Chang TK, Bellward GD. In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats. J Pharmacol Exp Ther 1998;284:493–9.Search in Google Scholar
23. Segal I. Enzyme kinetics. USA: John Wiley & Sons, Inc, 1975:931–3.Search in Google Scholar
©2015 by De Gruyter
